Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centene Corporation filings document operating and financial disclosures for a government-focused managed care company. Form 8-K reports furnish quarterly results press releases, GAAP and adjusted EPS guidance, non-GAAP financial measure disclosures, conference-related Regulation FD updates and material-event reports tied to company performance.
Centene's proxy and governance filings cover annual meeting matters, board and executive compensation disclosures, equity awards, officer appointments and related corporate governance topics. Other filings address material agreements, forward-looking-statement disclosures and formal exhibits filed or furnished with the SEC.
Centene Group President Michael A. Carson increased his deferred compensation exposure by acquiring 47.935 shares of phantom stock at $57.7700 per unit. Each phantom share represents the right to receive the fair market value of one Centene common share.
The phantom stock was obtained through regularly scheduled payroll contributions to the company’s deferred compensation plan and has no formal expiration date. After this award, Carson holds 604.004 phantom stock units, 122,882 shares of common stock held directly (including 113,747 restricted and performance stock units subject to vesting), and 825 common shares held indirectly by his spouse.
Centene Corporation executive Daniel P. Finke, Group President, Markets & Comm, has filed an initial ownership report showing compensation-based equity holdings in the company. The filing lists 228,127 restricted stock units, which are scheduled to vest in three equal installments on each anniversary of the grant date beginning April 15, 2027. These holdings represent stock-based awards rather than recent open-market share purchases or sales.
Centene Corp executive Michael A. Carson filed a Form 3 disclosing his initial equity interests in the company. He reports direct ownership of 122,882 shares of common stock and indirect ownership of 825 shares held by his spouse. He also holds 556.069 units of phantom stock, each linked to the value of one Centene common share and acquired through payroll contributions to the company’s deferred compensation plan.
Carson’s ownership further includes 57,619 previously awarded restricted stock units that vest between October 15, 2026 and March 15, 2027, and 56,128 performance stock units subject to three-year performance conditions, with potential vesting from 0% to 200% of target based on the company’s performance.
Centene Corporation reported the results of its annual shareholder meeting, where 412,968,059 shares of common stock were represented. All nine director nominees were elected, each receiving significantly more votes “for” than “against.”
Stockholders approved, on a non-binding advisory basis, the Company’s executive compensation, and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. A shareholder proposal requesting an independent board chairman did not pass. The Board also confirmed the executive officer team, including Sarah London as Chief Executive Officer and newly appointed group presidents Daniel Finke (Medicaid and Marketplace) and Michael Carson (Medicare and Specialty).
TANJI KENNETH reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp director Kenneth Tanji reported a stock award of 3,992 shares of common stock. The shares were granted at no cash cost to him as a compensation-related award and increase his direct holdings to 11,909 shares after the transaction.
According to the award terms, the 3,992 shares are in the form of restricted stock units that will vest in full on the earlier of May 12, 2027, or the date of Centene’s next annual meeting of stockholders.
Samuels Theodore R. II reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp director Theodore R. Samuels II received an equity grant of 3,992 shares of restricted stock units of Centene common stock. These units will vest in full on the earlier of May 12, 2027, or the date of Centene’s next annual meeting of stockholders. Following this grant, he holds 24,747.979 shares directly and 32,000 shares indirectly through a revocable family trust where he serves as co-trustee.
FORD MONTE E reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp director Monte E. Ford received a grant of 3,992 shares of common stock in the form of restricted stock units on May 12, 2026 at no cost. These units will vest in full on the earlier of May 12, 2027 or Centene’s next annual meeting of stockholders. Following this compensation award, Ford holds 14,826.771 shares directly, reflecting a routine equity-based director grant rather than an open-market purchase.
EPPINGER FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp reported that director Frederick H. Eppinger received an equity grant of 6,654 shares of Common Stock in the form of restricted stock units, recorded at a price of $0.00 per share as this is a compensation award rather than a market purchase.
The award will vest in full on the earlier of May 12, 2027 or the date of Centene’s next annual meeting of stockholders. Following this grant, Eppinger directly holds a total of 368,704.658 shares of Centene common stock.
Dallas H James reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp director James H. Dallas reported an equity award and updated share holdings. He received 3,992 shares of common stock in the form of restricted stock units at no cash cost. These units vest in full on the earlier of May 12, 2027, or the company’s next annual stockholder meeting.
Following this grant, Dallas directly holds 47,874.185 Centene common shares. He also indirectly holds 1,693 shares through a revocable family trust for which he serves as co-trustee. The filing reflects a compensation-related award rather than an open-market share purchase.
COUGHLIN CHRISTOPHER J reported acquisition or exercise transactions in this Form 4 filing.
Centene director Christopher J. Coughlin reported a new equity award and updated his holdings in Centene Corp. He received a grant of 3,992 shares of restricted stock units, which will vest in full on the earlier of May 12, 2027, or the date of Centene’s next annual stockholder meeting. Following this award, Coughlin directly holds 18,148.926 shares of Centene common stock. In addition, a grantor retained annuity trust for the benefit of Coughlin and his adult children holds 30,054 shares, which he reports as indirect ownership as sole trustee.